



HUTCHISON CHINA MEDITECH LTD

## Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM)

### Appointment of Joint Broker

**London:** Friday, 5 January 2007: Chi-Med today announces that it has appointed Investec Bank (UK) Limited as its Joint Broker effective on 5 January 2007. Panmure Gordon (Broking) Limited will continue to act as a broker to Chi-Med.

### Ends

#### Enquiries

**Chi-Med** Telephone: +852 2121 8200  
Christian Hogg, CEO

**Citigate Dewe Rogerson** Telephone: +44 (0) 20 7638 9571  
Anthony Carlisle +44 (0) 7973 611 888  
Chris Gardner +44 (0) 7903 737 649  
Yvonne Alexander +44 (0) 7866 610 682

#### Notes to Editors

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients. Its overall aim is to draw on the untapped wealth of knowledge and history of usage in the Traditional Chinese Medicine industry to develop products for the global market. The Company has three complementary businesses: drug R&D, China healthcare and consumer products.

Hutchison MediPharma is Chi-Med's wholly-owned drug research and development company and has a team of around 100 scientists and staff focusing on botanical drugs, semi-synthetic natural product drugs, and synthetic single chemical entity drugs. It currently has two candidates in clinical development in both the US and China. HMPL-002, a radiosensitiser for head and neck and non-small cell lung cancer ("NSCLC"), is in Phase I/II in the US and in proof of concept in China. HMPL-004, an inhibitor to a group of inflammatory cytokines, for treatment of inflammatory bowel diseases ("IBD"), including Crohn's Disease ("CD") and Ulcerative Colitis ("UC"), is in Phase II in the US and in proof of concept in China. Hutchison MediPharma also has a pipeline of single molecular entity discovery projects in the auto-immune/inflammatory diseases and oncology therapeutic areas which have shown activity against clinically validated targets.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.